Common Contracts
1 similar Development and Option Agreement contracts
CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option AgreementDevelopment and Option Agreement • February 19th, 2019
ZUG, Switzerland and CAMBRIDGE, Mass. and Durham, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced that a strategic collaboration, previously initiated in April 2017 to generate engineered AAV capsids with improved properties for in vivo gene editing programs, has now been expanded to include additional undisclosed applications. The financial terms of the new expanded development and option agreement have not been disclosed.
